Monthly Archives: September 2013

Where are we with Targeted Cancer Therapeutics?

In a recent project, I received a draft manuscript discussing targeted cancer therapeutics and companion diagnostics in which the writer made this statement: ”CML patients in treatment with Gleevec now have the same life expectancy as people without the disease, … Continue reading

Posted in Oncology, personalized medicine | Tagged , , , , | Comments Off on Where are we with Targeted Cancer Therapeutics?